Modality
Nanobody
MOA
EZH2i
Target
IL-17A
Pathway
DDR
CKD
Development Pipeline
Preclinical
Jul 2025
→ Feb 2030
PreclinicalCurrent
NCT05386699
1,171 pts·CKD
2025-07→2030-02·Terminated
1,171 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-163.9y awayInterim· CKD
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
Preclinical
Termina…
Catalysts
Interim
2030-02-16 · 3.9y away
CKD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05386699 | Preclinical | CKD | Terminated | 1171 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 |